Active — Not RecruitingNot Applicable

BRCA1/2 Flu Vaccine

United States50 participantsStarted 2019-10-28

Plain-language summary

To evaluate immune function in BRCA1/2 mutation carriers without cancer, specifically to determine whether immune function in healthy individuals with germline loss of function BRCA1/2 mutations, impacts overall immune health and fitness.

Who can participate

Age range25 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Males and females * Over age 25 * BRCA1 or BRCA2 pathogenic or likely pathogenic mutation * No personal cancer history apart from non melanoma skin cancer, localized thyroid cancer, in situ cancers of any type * Participants must sign the informed consent form Exclusion Criteria: * Are allergic to influenza vaccination * Have received influenza vaccination within the past 6 months * Require prednisone, methotrexate, or other immunosuppressing medications * Have HIV infection * Have a history of solid organ tumor or bone marrow transplant * Require combination immunotherapy; * Are on other studies requiring blood draws that might exceed 450 mL total during the period of the influenza vaccine study

What they're measuring

To evaluate immune function in female BRCA1/2 mutation carriers without cancer following seasonal influenza vaccination

Timeframe: 2 years

Trial details

NCT IDNCT04499534

SponsorAbramson Cancer Center at Penn Medicine

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-03

View on ClinicalTrials.gov More BRCA1 Mutation trials